Literature DB >> 18793526

Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity.

B Seiberlich1, N Hunzelmann, T Krieg, M Weber, E Schulze-Lohoff.   

Abstract

BACKGROUND: Renal involvement and systemic vascular damage have been shown to significantly affect prognosis in systemic sclerosis (SSc). However, it is often difficult to assess damage to the renal and systemic vasculature in SSc patients.
METHODS: Using detailed urinary protein analysis we sought to detect scleroderma renal disease at an early stage and to assess systemic vasculopathy due to SSc. We examined 80 patients with SSc as well as 18 healthy control subjects using urinary protein analysis including determination of urinary albumin excretion rate and urinary total protein excretion as well as urinary polyacrylamide gel electrophoresis.
RESULTS: Albuminuria was found in 25% (20/80) of the SSc patients (2.5% macroalbuminuria, 22.5% microalbuminuria), increased total protein excretion in 17.5% (14/80), and intermediate molecular weight proteinuria (IMWP) as determined by urine electrophoresis in 31.3% (25/80). None of these abnormalities was found in the control group (0/18). Presence of IMWP correlated with the diffuse type of SSc (p < 0.01), gastrointestinal involvement (p < 0.05) and increased systolic blood pressure (p < 0.01). Increased total protein excretion was found to correlate with pulmonary involvement (p < 0.05). Albuminuria was associated with prolonged duration of the disease (> 4 years) (p < 0.05) and increased systolic blood pressure (p < 0.01).
CONCLUSIONS: Leakage of proteins into the urine in patients with SSc appears to indicate not only renal involvement but also systemic vasculopathy which is associated with increased morbidity. Patients with SSc should be regularly examined using sensitive urinary protein tests such as albumin assays or urine electrophoresis, to detect kidney involvement at an early stage.

Entities:  

Mesh:

Year:  2008        PMID: 18793526     DOI: 10.5414/cnp70110

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  11 in total

1.  Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients?

Authors:  Amr Amin; S El-Sayed; N Taher; M Sedki; H Nasr
Journal:  Clin Rheumatol       Date:  2012-02-24       Impact factor: 2.980

Review 2.  Scleroderma renal crisis and renal involvement in systemic sclerosis.

Authors:  Thasia G Woodworth; Yossra A Suliman; Wendi Li; Daniel E Furst; Philip Clements
Journal:  Nat Rev Nephrol       Date:  2016-09-19       Impact factor: 28.314

Review 3.  Kidney involvement in systemic sclerosis: From pathogenesis to treatment.

Authors:  Cosimo Bruni; Giovanna Cuomo; Francesca W Rossi; Emanuela Praino; Silvia Bellando-Randone
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

4.  Renal manifestations in scleroderma: evidence for subclinical renal disease as a marker of vasculopathy.

Authors:  Victoria K Shanmugam; Virginia D Steen
Journal:  Int J Rheumatol       Date:  2010-08-17

5.  [Organ-specific diagnosis in patients with systemic sclerosis: Recommendations of the German Network for Systemic Sclerosis (DNSS)].

Authors:  N Hunzelmann; E Genth; T Krieg; M Meurer; I Melchers; P Moinzadeh; C Pfeiffer; G Riemekasten; E Schulze-Lohoff; C Sunderkoetter; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2008-07       Impact factor: 1.372

Review 6.  Points to consider in renal involvement in systemic sclerosis.

Authors:  Felice Galluccio; Ulf Müller-Ladner; Daniel E Furst; Dinesh Khanna; Marco Matucci-Cerinic
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 7.  Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management.

Authors:  Victoria K Shanmugam; Virginia D Steen
Journal:  Curr Opin Rheumatol       Date:  2012-11       Impact factor: 5.006

8.  Systemic sclerosis medications and risk of scleroderma renal crisis.

Authors:  S M Gordon; J B Hughes; R Nee; R S Stitt; W T Bailey; D J Little; J D Edison; S W Olson
Journal:  BMC Nephrol       Date:  2019-07-25       Impact factor: 2.388

9.  Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis.

Authors:  Shefali Khanna Sharma; Arghya Chattopadhyay; Siddharth Jain; Chitra Raj Sharma; Debashish Mishra; Manish Rathi; Mahesh Prakash; Sanjay Jain
Journal:  Mediterr J Rheumatol       Date:  2021-12-27

10.  Proteinuria in systemic sclerosis: reversal by ACE inhibition.

Authors:  J Schuster; P Moinzadeh; C Kurschat; T Benzing; T Krieg; M Weber; N Hunzelmann
Journal:  Rheumatol Int       Date:  2013-02-28       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.